Inhibition of Both Hsp70 Activity and Tau Aggregation in Vitro Best Predicts Tau Lowering Activity of Small Molecules

ACS Chemical Biology

Volumn 11, Issue 7, 2016, Pages 2041-2048

  Martin, Mackenzie D ^a   Baker, Jeremy D ^a   Suntharalingam, Amirthaa ^a   Nordhues, Bryce A ^a   Shelton, Lindsey B ^a   Zheng, Dali ^a   Sabbagh, Jonathan J ^a   Haystead, Timothy A J ^b   Gestwicki, Jason E ^c   Dickey, Chad A ^a,d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DERIVATIVE; AMINOTHIENOPYRIDAZINE; ANTHRAQUINONE; CARBOCYANINE; DIHYDROPYRIMIDINE; FLAVONOL; HEAT SHOCK PROTEIN 70; PHENOTHIAZINE; PHENOXY N ARYLACETAMIDE; PIPERIDINE 3 CARBOXAMIDE; POLYPHENOL; PROTEIN INHIBITOR; RHODACYANINE; RHODANINE; SULFONAMIDE; TAU PROTEIN; UNCLASSIFIED DRUG; MAPT PROTEIN, HUMAN; MOLECULAR LIBRARY;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; EMBRYO; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN AGGREGATION; ANTAGONISTS AND INHIBITORS; HEK293 CELL LINE; MOLECULAR LIBRARY; PHARMACOLOGY;

HEK293 CELLS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IN VITRO TECHNIQUES; SMALL MOLECULE LIBRARIES; TAU PROTEINS;

EID: 84978715674     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.6b00223     Document Type: Article

References (50)

1. Hardy, J. and Orr, H. (2006) The genetics of neurodegenerative diseases J. Neurochem. 97, 1690-1699 10.1111/j.1471-4159.2006.03979.x
2. McKee, A. C., Cantu, R. C., Nowinski, C. J., Hedley-Whyte, E. T., Gavett, B. E., Budson, A. E., Santini, V. E., Lee, H. S., Kubilus, C. A., and Stern, R. A. (2009) Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury J. Neuropathol. Exp. Neurol. 68, 709-735 10.1097/NEN.0b013e3181a9d503
3. Gerson, J. E., Castillo-Carranza, D. L., and Kayed, R. (2014) Advances in Therapeutics for Neurodegenerative Tauopathies: Moving toward the Specific Targeting of the Most Toxic Tau Species ACS Chem. Neurosci. 5, 752-769 10.1021/cn500143n
4. Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., Burns, M., Krishnamurthy, P., Wen, Y., Bhat, R., Lewis, J., Dickson, D., and Duff, K. (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo Proc. Natl. Acad. Sci. U. S. A. 102, 6990-6995 10.1073/pnas.0500466102
5. Piette, F., Belmin, J., Vincent, H., Schmidt, N., Pariel, S., Verny, M., Marquis, C., Mely, J., Hugonot-Diener, L., Kinet, J. P., Dubreuil, P., Moussy, A., and Hermine, O. (2011) Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial Alzheimer's Res. Ther. 3, 16 10.1186/alzrt75
6. Pickhardt, M., Gazova, Z., von Bergen, M., Khlistunova, I., Wang, Y., Hascher, A., Mandelkow, E. M., Biernat, J., and Mandelkow, E. (2005) Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells J. Biol. Chem. 280, 3628-3635 10.1074/jbc.M410984200
7. Brunden, K. R., Trojanowski, J. Q., and Lee, V. M. (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies Nat. Rev. Drug Discovery 8, 783-793 10.1038/nrd2959
8. Abisambra, J., Jinwal, U. K., Miyata, Y., Rogers, J., Blair, L., Li, X., Seguin, S. P., Wang, L., Jin, Y., Bacon, J., Brady, S., Cockman, M., Guidi, C., Zhang, J., Koren, J., Young, Z. T., Atkins, C. A., Zhang, B., Lawson, L. Y., Weeber, E. J., Brodsky, J. L., Gestwicki, J. E., and Dickey, C. A. (2013) Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau Biol. Psychiatry 74, 367-374 10.1016/j.biopsych.2013.02.027
9. Jinwal, U. K., Miyata, Y., Koren, J., 3rd, Jones, J. R., Trotter, J. H., Chang, L., O'Leary, J., Morgan, D., Lee, D. C., Shults, C. L., Rousaki, A., Weeber, E. J., Zuiderweg, E. R., Gestwicki, J. E., and Dickey, C. A. (2009) Chemical manipulation of hsp70 ATPase activity regulates tau stability J. Neurosci. 29, 12079-12088 10.1523/JNEUROSCI.3345-09.2009
10. Jinwal, U. K., Koren, J., O'Leary, J. C., Jones, J. R., Abisambra, J. F., and Dickey, C. A. (2010) Hsp70 ATPase Modulators as Therapeutics for Alzheimer's and other Neurodegenerative Diseases Mol. Cell Pharmacol 2, 43-46
11. Martin, M. D., Calcul, L., Smith, C., Jinwal, U. K., Fontaine, S. N., Darling, A., Seeley, K., Wojtas, L., Narayan, M., Gestwicki, J. E., Smith, G. R., Reitz, A. B., Baker, B. J., and Dickey, C. A. (2015) Synthesis, Stereochemical Analysis, and Derivatization of Myricanol Provide New Probes That Promote Autophagic Tau Clearance ACS Chem. Biol. 10, 1099 10.1021/cb501013w
12. Dickey, C. A., Eriksen, J., Kamal, A., Burrows, F., Kasibhatla, S., Eckman, C. B., Hutton, M., and Petrucelli, L. (2005) Development of a high throughput drug screening assay for the detection of changes in tau levels - proof of concept with HSP90 inhibitors Curr. Alzheimer Res. 2, 231-238 10.2174/1567205053585927
13. Jones, J. R., Lebar, M. D., Jinwal, U. K., Abisambra, J. F., Koren, J., 3rd, Blair, L., O'Leary, J. C., Davey, Z., Trotter, J., Johnson, A. G., Weeber, E., Eckman, C. B., Baker, B. J., and Dickey, C. A. (2011) The diarylheptanoid (+)-aR,11S-myricanol and two flavones from bayberry (Myrica cerifera) destabilize the microtubule-associated protein tau J. Nat. Prod. 74, 38-44 10.1021/np100572z
14. Fontaine, S. N., Martin, M. D., Akoury, E., Assimon, V. A., Borysov, S., Nordhues, B. A., Sabbagh, J. J., Cockman, M., Gestwicki, J. E., Zweckstetter, M., and Dickey, C. A. (2015) The active Hsc70/tau complex can be exploited to enhance tau turnover without damaging microtubule dynamics Hum. Mol. Genet. 24, 3971-3981 10.1093/hmg/ddv135
15. Thompson, A. D., Scaglione, K. M., Prensner, J., Gillies, A. T., Chinnaiyan, A., Paulson, H. L., Jinwal, U. K., Dickey, C. A., and Gestwicki, J. E. (2012) Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation ACS Chem. Biol. 7, 1677-1686 10.1021/cb3002599
16. Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., and Sulzer, D. (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy Science 305, 1292-1295 10.1126/science.1101738
17. Auluck, P. K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M., and Bonini, N. M. (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease Science 295, 865-868 10.1126/science.1067389
18. Udan-Johns, M., Bengoechea, R., Bell, S., Shao, J., Diamond, M. I., True, H. L., Weihl, C. C., and Baloh, R. H. (2014) Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones Hum. Mol. Genet. 23, 157-170 10.1093/hmg/ddt408
19. Williamson, D. S., Borgognoni, J., Clay, A., Daniels, Z., Dokurno, P., Drysdale, M. J., Foloppe, N., Francis, G. L., Graham, C. J., Howes, R., Macias, A. T., Murray, J. B., Parsons, R., Shaw, T., Surgenor, A. E., Terry, L., Wang, Y., Wood, M., and Massey, A. J. (2009) Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design J. Med. Chem. 52, 1510-1513 10.1021/jm801627a
20. Massey, A. J., Williamson, D. S., Browne, H., Murray, J. B., Dokurno, P., Shaw, T., Macias, A. T., Daniels, Z., Geoffroy, S., Dopson, M., Lavan, P., Matassova, N., Francis, G. L., Graham, C. J., Parsons, R., Wang, Y., Padfield, A., Comer, M., Drysdale, M. J., and Wood, M. (2010) A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells Cancer Chemother. Pharmacol. 66, 535-545 10.1007/s00280-009-1194-3
21. Chang, L., Bertelsen, E. B., Wisen, S., Larsen, E. M., Zuiderweg, E. R., and Gestwicki, J. E. (2008) High-throughput screen for small molecules that modulate the ATPase activity of the molecular chaperone DnaK Anal. Biochem. 372, 167-176 10.1016/j.ab.2007.08.020
22. Miyata, Y., Rauch, J. N., Jinwal, U. K., Thompson, A. D., Srinivasan, S., Dickey, C. A., and Gestwicki, J. E. (2012) Cysteine reactivity distinguishes redox sensing by the heat-inducible and constitutive forms of heat shock protein 70 Chem. Biol. 19, 1391-1399 10.1016/j.chembiol.2012.07.026
23. Li, X., Srinivasan, S. R., Connarn, J., Ahmad, A., Young, Z. T., Kabza, A. M., Zuiderweg, E. R., Sun, D., and Gestwicki, J. E. (2013) Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents ACS Med. Chem. Lett. 4, 1042 10.1021/ml400204n
24. Kang, Y., Taldone, T., Patel, H. J., Patel, P. D., Rodina, A., Gozman, A., Maharaj, R., Clement, C. C., Patel, M. R., Brodsky, J. L., Young, J. C., and Chiosis, G. (2014) Heat shock protein 70 inhibitors. 1. 2,5′-thiodipyrimidine and 5-(phenylthio)pyrimidine acrylamides as irreversible binders to an allosteric site on heat shock protein 70 J. Med. Chem. 57, 1188-1207 10.1021/jm401551n
25. Taldone, T., Kang, Y., Patel, H. J., Patel, M. R., Patel, P. D., Rodina, A., Patel, Y., Gozman, A., Maharaj, R., Clement, C. C., Lu, A., Young, J. C., and Chiosis, G. (2014) Heat shock protein 70 inhibitors. 2. 2,5′-thiodipyrimidines, 5-(phenylthio)pyrimidines, 2-(pyridin-3-ylthio)pyrimidines, and 3-(phenylthio)pyridines as reversible binders to an allosteric site on heat shock protein 70 J. Med. Chem. 57, 1208-1224 10.1021/jm401552y
26. Cassel, J. A., Ilyin, S., McDonnell, M. E., and Reitz, A. B. (2012) Novel inhibitors of heat shock protein Hsp70-mediated luciferase refolding that bind to DnaJ Bioorg. Med. Chem. 20, 3609-3614 10.1016/j.bmc.2012.03.067
27. Leu, J. I., Pimkina, J., Frank, A., Murphy, M. E., and George, D. L. (2009) A small molecule inhibitor of inducible heat shock protein 70 Mol. Cell 36, 15-27 10.1016/j.molcel.2009.09.023
28. Schlecht, R., Scholz, S. R., Dahmen, H., Wegener, A., Sirrenberg, C., Musil, D., Bomke, J., Eggenweiler, H. M., Mayer, M. P., and Bukau, B. (2013) Functional analysis of Hsp70 inhibitors PLoS One 8, e78443 10.1371/journal.pone.0078443
29. Crowe, A., James, M. J., Lee, V. M., Smith, A. B., 3rd, Trojanowski, J. Q., Ballatore, C., and Brunden, K. R. (2013) Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation J. Biol. Chem. 288, 11024-11037 10.1074/jbc.M112.436006
30. Akoury, E., Pickhardt, M., Gajda, M., Biernat, J., Mandelkow, E., and Zweckstetter, M. (2013) Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation Angew. Chem., Int. Ed. 52, 3511-3515 10.1002/anie.201208290
31. Kuret, J., Chirita, C. N., Congdon, E. E., Kannanayakal, T., Li, G., Necula, M., Yin, H., and Zhong, Q. (2005) Pathways of tau fibrillization Biochim. Biophys. Acta, Mol. Basis Dis. 1739, 167-178 10.1016/j.bbadis.2004.06.016
32. Walker, S., Ullman, O., and Stultz, C. M. (2012) Using intramolecular disulfide bonds in tau protein to deduce structural features of aggregation-resistant conformations J. Biol. Chem. 287, 9591-9600 10.1074/jbc.M111.336107
33. Di Noto, L., DeTure, M. A., and Purich, D. L. (1999) Disulfide-cross-linked tau and MAP2 homodimers readily promote microtubule assembly Mol. Cell Biol. Res. Commun. 2, 71-76 10.1006/mcbr.1999.0153
34. Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., and Harrington, C. R. (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines Proc. Natl. Acad. Sci. U. S. A. 93, 11213-11218 10.1073/pnas.93.20.11213
35. Hosokawa, M., Arai, T., Masuda-Suzukake, M., Nonaka, T., Yamashita, M., Akiyama, H., and Hasegawa, M. (2012) Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice PLoS One 7, e52389 10.1371/journal.pone.0052389
36. Hochgrafe, K., Sydow, A., Matenia, D., Cadinu, D., Konen, S., Petrova, O., Pickhardt, M., Goll, P., Morellini, F., Mandelkow, E., and Mandelkow, E. M. (2015) Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau Acta Neuropathol Commun. 3, 25 10.1186/s40478-015-0204-4
37. Wischik, C. and Staff, R. (2009) Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy J. Nutr., Health Aging 13, 367-369 10.1007/s12603-009-0046-5
38. Wischik, C. M., Harrington, C. R., and Storey, J. M. (2013) Tau-aggregation inhibitor therapy for Alzheimer's disease Biochem. Pharmacol. 88, 529 10.1016/j.bcp.2013.12.008
39. Bulic, B., Pickhardt, M., Mandelkow, E. M., and Mandelkow, E. (2010) Tau protein and tau aggregation inhibitors Neuropharmacology 59, 276-289 10.1016/j.neuropharm.2010.01.016
40. Bulic, B., Pickhardt, M., Khlistunova, I., Biernat, J., Mandelkow, E. M., Mandelkow, E., and Waldmann, H. (2007) Rhodanine-based tau aggregation inhibitors in cell models of tauopathy Angew. Chem., Int. Ed. 46, 9215-9219 10.1002/anie.200704051
41. Ballatore, C., Brunden, K. R., Piscitelli, F., James, M. J., Crowe, A., Yao, Y., Hyde, E., Trojanowski, J. Q., Lee, V. M., and Smith, A. B., 3rd. (2010) Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation J. Med. Chem. 53, 3739-3747 10.1021/jm100138f
42. Daccache, A., Lion, C., Sibille, N., Gerard, M., Slomianny, C., Lippens, G., and Cotelle, P. (2011) Oleuropein and derivatives from olives as Tau aggregation inhibitors Neurochem. Int. 58, 700-707 10.1016/j.neuint.2011.02.010
43. Pouliot, M. and Jeanmart, S. (2016) Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research J. Med. Chem. 59, 497-503 10.1021/acs.jmedchem.5b00361
44. Baell, J. B. and Holloway, G. A. (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 53, 2719-2740 10.1021/jm901137j
45. Dickey, C. A., Ash, P., Klosak, N., Lee, W. C., Petrucelli, L., Hutton, M., and Eckman, C. B. (2006) Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression Mol. Neurodegener. 1, 6 10.1186/1750-1326-1-6
46. Dickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., Patterson, C., Dickson, D. W., Nahman, N. S., Jr., Hutton, M., Burrows, F., and Petrucelli, L. (2007) The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins J. Clin. Invest. 117, 648-658 10.1172/JCI29715
47. Repalli, J. and Meruelo, D. (2015) Screening strategies to identify HSP70 modulators to treat Alzheimer's disease Drug Des., Dev. Ther. 9, 321-331 10.2147/DDDT.S72165
48. Rodriguez-Franco, M. I., Fernandez-Bachiller, M. I., Perez, C., Hernandez-Ledesma, B., and Bartolome, B. (2006) Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties J. Med. Chem. 49, 459-462 10.1021/jm050746d
49. Tang, C., Li, C., Zhang, S., Hu, Z., Wu, J., Dong, C., Huang, J., and Zhou, H. B. (2015) Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer J. Med. Chem. 58, 4550-4572 10.1021/acs.jmedchem.5b00099
50. Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Cote, S., Shoichet, B. K., and Urban, L. (2012) Large-scale prediction and testing of drug activity on side-effect targets Nature 486, 361-367 10.1038/nature11159